MERZ-AESTHETICS
3.6.2022 09:02:06 CEST | Business Wire | Press release
Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 2022 International Master Course on Aging Science (IMCAS) World Congress, with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diversifying society and a younger patient base. IMCAS, held from Friday, June 3 to Sunday, June 5, 2022, will take place in a hybrid format, enabling participants to attend the conference in person in Paris and/or virtually. Merz Aesthetics is a diamond sponsor of the global industry congress.
“This year’s IMCAS Congress is an opportunity to reunite with our partners and leading experts in dermatology, plastic surgery and aging science to bridge our respective fields and drive innovation in aesthetic medicine forward,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics. “We exist to fuel confidence by helping people look better, feel better and live better, and we’re proud to present research across our portfolio that reinforces the need for diverse and expansive experiences for every patient.”
Merz Aesthetics continues to embrace the diversified and unique needs of aesthetic patients and practitioners, recognizing the personal journey for each patient and partnering with experts to meet those needs. As patients are starting their aesthetic journey earlier in their lives, Merz Aesthetics stands for a long term and responsible view on how patients are treated.
Merz Aesthetics is organizing a program led by esteemed medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the course of the meeting.
- Merz Aesthetics Symposium #Beautification – Embracing #Uniqueness, Advanced aesthetic strategies for the needs of diverse generations – Dr. Gabriela Casabona, Dr. Daria Voropai, Dr. Raj Aquilla, Sunday, June 5, 2022 | 10:30 – 12:30h CEST
- Merz Aesthetics support of IMCAS Cadaver Workshop with anatomist Prof. Dr. Thilo Schenck and Live Injector: Dr. Fouad Belfkira - Friday, June 3, 2022 10:30 – 11:00h CEST
- Product Analysis Session “Emerging Toxins”, Andy Curry, Assoc. Med. Director, Merz Aesthetics - Friday, June 3, 2022, 8:30 - 12:00 h CEST
- Innovation Tank, Dr. Samantha Kerr, CSO, Merz Aesthetics, Friday, June 3, 2022, 8:30 -12:00h CEST
- IMCAS Economic Tribune Round Table, Bob Rhatigan, CEO Merz Aesthetics, Saturday, June 4, 2022, 16:00 – 18:00h CEST
E-Poster Presentations
Virtual posters will be available for viewing on site for the duration of the congress and displayed on the virtual E-poster platform with detailed abstracts.
Botulinum Toxin
- Study Design of LONG RUN: A longitudinal evaluation and real-world evidence of uniquely purified incobotulinumtoxinA in treatment naïve participants. Presenting author: Andy Curry , Merz Aesthetics – USA, Terrence Keaney, MD – USA, Karyn Siemasko, PhD -USA
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results. Martina Kerscher, MD PhD – Germany, Sabrina Fabi, Md – USA, Tanja Fischer, MD PhD – Germany, Presenting author: Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, PhD – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
Belotero® and Radiesse®
- A Hybrid Filler: Combining Calcium Hydroxylapatite and Hyaluronic Acid Fillers for Aesthetic Indications, Presenting author: Jonathan Kadouch , MD, PhD – Netherlands, Nabil Fakih-Gomez, MD-Lebanon.
- Comparative Histomorphological Evaluation of the Injectable Cohesive Polydensified Matrix Hyaluronic Acid and Calcium Hydroxylapatite Combination. Presenting author: Yana Yutskovskaya , MD – Russia, Evgenia Kogan, MD PhD – Russia, Alla Y Koroleva, MD – Russia.
- Technical evaluation and comparison of calcium hydroxylapatite (CaHA) containing dermal fillers, Sarah Backfisch, Radia El-Banna, Presenting author: Cleiton Kunzler , Roland Stragies, and Nadine Hagedorn, Merz Aesthetics GmbH – Germany.
- Increased hyaluronic acid concentration enhances the local tissue lifting capacity in an ex vivo human skin model, Kay Marquardt, Christian Hartmann, Christina Wollenburg, Tristan Gesing, Presenting author: Thomas Hengl, Merz Aesthetics GmbH – Germany.
- Animal study indicates importance of distance between microspheres for neocollagenesis, Bartosch Nowag, Nils Warfving, Presenting author: Thomas Hengl, Merz Aesthetics GmbH – Germany.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves—however they define it. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with a commercial presence in 36 countries worldwide. Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2022 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom